scholarly journals Injectable Polyethylene Glycol Gel as Dermal Filler: 01 Year Clinical and Ultrasound Follow-Up

2016 ◽  
Vol 07 (02) ◽  
Author(s):  
Flávia AS Addor ◽  
Simone R Nogueira Guerra Neri
Keyword(s):  
Polyethylene Glycol ◽  
Dermal Filler

scholarly journals Toward Physicochemical and Rheological Characterization of Different Injectable Hyaluronic Acid Dermal Fillers Cross-Linked with Polyethylene Glycol Diglycidyl Ether

Polymers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 948
Author(s):  
Nicola Zerbinati ◽  
Sabrina Sommatis ◽  
Cristina Maccario ◽  
Maria Chiara Capillo ◽  
Giulia Grimaldi ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Polyethylene Glycol ◽  
Biological Activities ◽  
Diglycidyl Ether ◽  
Dermal Filler ◽  
Cross Linking ◽  
Matrix Structure ◽  
Dermal Fillers ◽  
Rheological Characterization

(1) Background: Injectable hyaluronic acid (HA) dermal fillers are used to restore volume, hydration and skin tone in aesthetic medicine. HA fillers differ from each other due to their cross-linking technologies, with the aim to increase mechanical and biological activities. One of the most recent and promising cross-linkers is polyethylene glycol diglycidyl ether (PEGDE), used by the company Matex Lab S.p.A., (Brindisi, Italy) to create the HA dermal filler PEGDE family. Over the last few years, several studies have been performed to investigate the biocompatibility and biodegradability of these formulations, but little information is available regarding their matrix structure, rheological and physicochemical properties related to their cross-linking technologies, the HA content or the degree of cross-linking. (2) Methods: Seven different injectable HA hydrogels were subjected to optical microscopic examination, cohesivity evaluation and rheological characterization in order to investigate their behavior. (3) Results: The analyzed cross-linked dermal fillers showed a fibrous “spiderweb-like” matrix structure, with each medical device presenting different and peculiar rheological features. Except for HA non cross-linked hydrogel 18 mg/mL, all showed an elastic and cohesive profile. (4) Conclusions: The comparative analysis with other literature works makes a preliminary characterization of these injectable medical devices possible.

Microcannula Utilization for Injectable Facial Fillers: Standard of Care?

2018 ◽  
Vol 35 (4) ◽  
pp. 189-197 ◽  
Author(s):  
Kian Karimi ◽  
Chester F. Griffiths ◽  
Alex Reivitis ◽  
Austin Davis-Hunter ◽  
Elizabeth Zhang ◽  
...  
Keyword(s):  
Adverse Events ◽  
Electronic Medical Records ◽  
Medical Records ◽  
Standard Of Care ◽  
Dermal Filler ◽  
Popular Method ◽  
Patient Reported ◽  
Clinical Series ◽  
Filler Injections

The microcannula technique has become an increasingly popular method for injecting cosmetic fillers. Previous studies have illustrated that the microcannula technique allows filler to be injected with less pain, swelling, and essentially no bruising. This study is a retrospective clinical series examining 247 patients who have undergone dermal filler injections using the microcannula technique from 2011 to 2016 with a single injector, Kian Karimi. The purpose of this study is to assess the frequency of adverse events associated with injections such as bruising and swelling. All 666 recorded patient visits from 2011 to 2016 were analyzed using electronic medical records based on the criteria that the patients had cosmetic filler using the microcannula technique by the surgeon investigator. Of the 666 filler treatments using the microcannula technique, 3 treatments (0.5%) produced adverse events on the day of service, and 32 treatments (4.8%) produced adverse events at 2-week follow-up. In total, 5.4% of treatments produced adverse events. At the 2-week follow-up, 5.7% of treatments using the 25-gauge microcannula produced adverse events ( P = .830); 3.9% of treatments using the 27-gauge microcannula produced adverse events ( P = .612]). Only 3 patients were treated with the 30-gauge microcannula, and 1 patient reported adverse events on the day of service. None of the treatments using the 30-gauge microcannula produced adverse events at the 2-week follow-up ( P = .160). The data support that the microcannula technique is a safe and effective alternative to hypodermic needles for the injection of dermal filler to minimize common adverse events.

Hand Rejuvenation With A Hyaluronic Acid-Based Dermal Filler: A 12-Month Clinical Follow-Up Case Series

2021 ◽  
Vol 20 (4) ◽  
pp. 451-459
Author(s):  
Patrick Micheels ◽  
Stéphanie Besse ◽  
Marc Sibon ◽  
Badwi Elias
Keyword(s):  
Hyaluronic Acid ◽  
Case Series ◽  
Dermal Filler ◽  
Hand Rejuvenation

Repair of middle fossa cerebrospinal fluid leaks using a novel combination of materials: technical note

2012 ◽  
Vol 32 (6) ◽  
pp. E8 ◽  
Author(s):  
Cedric D. Shorter ◽  
David E. Connor ◽  
Jai Deep Thakur ◽  
Gale Gardner ◽  
Anil Nanda ◽  
...  
Keyword(s):  
Polyethylene Glycol ◽  
Middle Fossa ◽  
Inclusion Criteria ◽  
Csf Rhinorrhea ◽  
Dural Substitute ◽  
Synthetic Materials ◽  
Csf Leakage ◽  
Hydroxyapatite Cement ◽  
Csf Leaks

Object Methods for repairing middle fossa CSF (MFCSF) leaks have varied and yielded mixed results. The objective of this study was to evaluate the safety and durability of the authors' repair technique using a novel combination of 3 synthetic materials. Methods The authors performed a retrospective case review of patients treated for CSF leaks between January 2009 and September 2011. Eight patients were found to have undergone middle fossa craniotomies for CSF leaks. Inclusion criteria for the study included age greater than 18 years, neuroimaging-documented temporal bone defect, and symptoms consistent with CSF leaks or gross CSF otorrhea. Seven patients, 3 men and 4 women, met the inclusion criteria, and their charts were reviewed. Hydroxyapatite cement, collagen-based dural substitute matrix, and polyethylene glycol hydrogel sealant were used in all patients for the repair. Results In all patients the MFCSF leaks were successfully repaired. Initial presenting symptoms included CSF otorrhea in 4 patients (57.1%), hearing loss in 3 (42.9%), and CSF rhinorrhea in 1 (14.3%). The mean follow-up duration was 12 months (range 5–33 months). In 1 patient an epidural hematoma developed at the operative site on postoperative Day 2, and in another patient a superficial wound dehiscence occurred on postoperative Day 48. During the follow-up period, the authors found no evidence of wound infections, neurovascular damage, or CSF leakage requiring reoperation. Conclusions The middle fossa approach involving a combination of hydroxyapatite cement, collagen-based dural substitute matrix, and polyethylene glycol hydrogel sealant is a safe, effective method for repairing MFCSF leaks. The combination of synthetic materials provides an alternative to existing materials for skull base surgeons.

scholarly journals Polyethylene glycol-coated collagen patch (hemopatch®) in open partial nephrectomy

2021 ◽  
Author(s):  
Michael Staehler ◽  
S. Rodler ◽  
M. Schott ◽  
J. Casuscelli ◽  
C. Stief ◽  
...  
Keyword(s):  
Renal Function ◽  
Polyethylene Glycol ◽  
Blood Loss ◽  
Partial Nephrectomy ◽  
Low Complexity ◽  
High Complexity ◽  
Open Partial Nephrectomy ◽  
Duration Of Surgery ◽  
Coated Collagen

Abstract Purpose To describe the results of a polyethylene glycol-coated collagen patch, Hemopatch® on blood loss, surgical time and renal function in partial nephrectomy (PN) for renal cell carcinoma (RCC). Methods Out of a single surgeon cohort of n = 565 patients undergoing conventional open PN (CPN) between 01/2015 and 12/2017 at the University of Munich a consecutive subgroup (n = 42) was operated on using a polyethylene glycol-coated collagen-based sealant Hemopatch® (Baxter International Inc., Deerfield, IL, USA) (HPN). Results Median age was 65.2 years (range 12.7–95.2) with median follow-up of 9.43 months (0.03–49.15). Baseline renal function (CKD-EPI) was 78.56 ml/min/1.73 m2 (range 20.38–143.09) with a non-significant decline to 74.78 ml/min/1.73 m2 (range 3.75–167.74) at follow-up. In CPN 46% had low complexity, 33% moderate complexity and 20% high complexity lesions with 33% low, 40% moderate and 27% high complexity masses in HPN. Median tumor size was 4.3 cm (range 1–38 cm) in CPN with 4.8 cm (range 3.8–18.3 cm) with HPN, p = 0.293. Median blood loss and duration of surgery was significantly lower in the HPN group vs. CPN (146 ml ± 195 vs. 114 ml ± 159 ml; p = 0.021; 43 min ± 27 for HPN vs. 53 min ± 49; p = 0.035) with no difference in clamping time (12.6 min ± 8.6 for HPN vs. 12.0 min ± 9.5; p = 0.701). Conclusions Hemopatch® supported renoraphy shows promising results compared to standard renoraphy in PN. No side effects were seen. Further studies should evaluate the prevention of arterio-venous or urinary fistulas. In complex partial nephrectomies Hemopatch® supported renoraphy should be considered.

MR enterography with polyethylene glycol as oral contrast medium in the follow-up of patients with Crohn disease: comparison with CT enterography

2009 ◽  
Vol 35 (5) ◽  
pp. 563-570 ◽  
Author(s):  
Davide Ippolito ◽  
Francesca Invernizzi ◽  
Stefania Galimberti ◽  
Maria Rita Panelli ◽  
Sandro Sironi
Keyword(s):  
Polyethylene Glycol ◽  
Contrast Medium ◽  
Crohn Disease ◽  
Mr Enterography ◽  
Oral Contrast ◽  
Ct Enterography ◽  
Oral Contrast Medium

Purified Polydimethylsiloxane (Silicone) as Dermal Filler Resolving the Controversy?

2018 ◽  
Vol 36 (2) ◽  
pp. 71-77 ◽  
Author(s):  
Ehab Akkary ◽  
Robert Shumway ◽  
Jay Barnett
Keyword(s):  
Retrospective Chart Review ◽  
Adverse Outcomes ◽  
Dermal Filler ◽  
Off Label Use ◽  
Off Label ◽  
Permanent Filler ◽  
Nasolabial Folds ◽  
Silicone Migration ◽  
Label Use

Dermal fillers are widely used in Medical and Surgical Cosmetic practices. Temporary and semipermanent fillers are more commonly used for a wide variety of reasons; however, permanent fillers represent an excellent option in properly selected patients. The aim of this study is to evaluate the off-label use of Silikon 1000 (S1000) as a permanent filler analyzing safety, durability, and patient satisfaction. This was a retrospective chart review of prospectively collected data. The study included 25 patients who underwent S1000 injection in 32 treatment areas. The following parameters were assessed: age, gender, weight, height, body mass index (BMI), number of treatments, duration of treatments, follow-up, complications, and interventions. Patients who had other fillers injected into the same area within 1 year before or after the S1000 injection were excluded from the study. In all, 32 treatment areas in 25 patients (21 females, 4 males) were included in the study. Five female patients received S1000 in more than one area. Treatment areas included the following: nose (n = 4), lips (n = 16), glabella (n = 4), nasolabial folds (n = 3), scars (acne or others) (n = 2), orbital rim (n = 2), and perioral (n = 1). Extrusion of silicone, migration, cosmetic deformity, hematoma, seroma, and infection were considered as inclusive criteria for injection complications. None of the patients developed any complications along the course of follow-up that ranged from 8-38 months; therefore, no intervention or surgery was needed to treat any adverse outcomes. All patients reported high satisfaction with the cosmetic results. Off-label use of highly purified polydimethylsiloxane as dermal filler is safe and durable. Being conservative is key to optimize outcomes and avoid complications. Proper approach involves injection of small doses using microdroplet technique to augment the tissue gradually over sessions at 1-2 months apart. Complications as silicone migration and irregularities can be largely avoided by following proper techniques and understanding the unique mechanism of action of S1000 compared with traditional fillers.

scholarly journals Macrocalcitonin Is a Novel Pitfall in the Routine of Serum Calcitonin Immunoassay

2016 ◽  
Vol 101 (2) ◽  
pp. 653-658 ◽  
Author(s):  
Thalita G. Alves ◽  
Teresa S. Kasamatsu ◽  
Ji H. Yang ◽  
Maria Cecília Z. Meneghetti ◽  
Aline Mendes ◽  
...  
Keyword(s):  
Polyethylene Glycol ◽  
Protein A ◽  
Ultra Performance Liquid Chromatography ◽  
Primary Diagnosis ◽  
Surgical Removal ◽  
Serum Calcitonin ◽  
Before And After ◽  
Structural Disease ◽  
Assay Interference

Context: Calcitonin (CT) is a sensitive marker of medullary thyroid carcinoma (MTC) and is used for primary diagnosis and follow-up after thyroidectomy. However, persistently elevated CT is observed even after complete surgical removal without evidence of a recurrent or persistent tumor. Objective: To investigate the presence of assay interference in the serum CT of MTC patients who are apparently without a structural disease. Patients and Methods: We studied three index MTC cases for CT assay interference and 14 patients with metastatic MTC. The CT level was measured using an immunofluorometric assay. Screening for assay interference was performed by determination of CT levels before and after serum treatment with polyethylene glycol. Additionally, samples were analyzed by chromatography on ultra-performance liquid chromatography and protein A-Sepharose. Results: Patients with biochemical and structural disease showed CT mean recovery of 84.1% after polyethylene glycol treatment, whereas patients suspected of interference showed recovery from 2–7%. The elution profile on UPLC showed that the immunometric CT from these three patients behaved like a high molecular mass aggregate (>300 kDa). Additionally, when these samples were applied to the protein A-Sepharose, CT immunoreactivity was retained on the column and was only released after lowering the pH. Conclusions: For the first time, our results show the presence of a novel pitfall in the CT immunoassay: “macrocalcitonin.” Its etiology, frequency, and meaning remain to be defined, but its recognition is of interest and can help clinicians avoid unnecessary diagnostic investigations and treatment during the follow-up of MTC.

Sign in / Sign up

Export Citation Format

Share Document